Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2021-11-11 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
关于新乡拓新药业股份有限公司以自筹资金预先投入募集资金投资项目情况的鉴定报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Verification Report) regarding the use of self-raised funds to pre-invest in projects intended to be funded by raised capital. It is issued by a certified public accounting firm and addresses the shareholders of the company. The content includes verification of the company's pre-investment using self-raised funds before the official raised capital was received, consistent with regulatory requirements from the Shenzhen Stock Exchange and the China Securities Regulatory Commission. The document contains detailed financial figures and audit verification statements but is not a full annual or interim financial report. It is a standalone audit-related verification report focused on a specific aspect of the company's capital use and compliance, rather than a comprehensive financial statement or management discussion. Therefore, it fits the category of an Audit Report / Information (AR). The document length is under 5,000 characters but contains substantive audit content, not merely an announcement or certification letter, so it is not RPA or RNS. Hence, the classification is AR with high confidence.
2021-11-11 Chinese
中天国富证券有限公司关于公司使用部分闲置募集资金用于暂时补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed opinion and verification report by a sponsoring securities company regarding the use of idle raised funds by a listed company to temporarily supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the amount and purpose of the funds, and includes approvals from the board, supervisory board, and independent directors. The document is focused on the use of raised funds and compliance with regulatory requirements rather than announcing a new financing event or capital change. It is not a full annual or interim financial report, nor is it a brief announcement or certification. The document length is 2780 characters, which is relatively short but contains substantive content about the use of raised funds and regulatory compliance. This type of document aligns best with a Capital/Financing Update (CAP) as it provides an update on the use of capital raised through an IPO and its temporary allocation to working capital, including regulatory and board approvals.
2021-11-11 Chinese
内幕知情人登记管理制度
Regulatory Filings Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System' for Xinxiang Tuoxin Pharmaceutical Co., Ltd. It is a detailed internal policy document outlining the management, registration, confidentiality, and responsibilities related to insider information and insider persons. It references relevant laws and regulations, describes procedures for insider registration, confidentiality obligations, and legal responsibilities. The document includes attachments such as insider registration forms, major event progress memorandums, and insider trading prevention reminder letters. There is no financial data, earnings information, or report publication announcement. It is a regulatory compliance and governance-related internal policy document. Therefore, it best fits the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance document that does not fit other specific categories.
2021-11-11 Chinese
关于召开2021年第二次临时股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice for convening the 2021 second extraordinary general meeting of shareholders of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes information about the meeting date, time, venue, agenda items, voting procedures, registration details, and proxy forms. The content focuses on informing shareholders about the meeting and how to participate and vote on specific proposals. There are no financial statements, audit opinions, or management discussions of financial results. The document is not a report itself but a formal announcement and invitation to a shareholders' meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 4970 characters, which is consistent with a detailed meeting notice rather than a full report or voting results announcement.
2021-11-11 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled "新乡拓新药业股份有限公司 信息披露管理制度" which translates to "Information Disclosure Management System" of the company. It outlines the company's policies, procedures, and responsibilities regarding information disclosure, including references to laws, regulations, and internal controls. It discusses the types of reports to be disclosed (annual reports, interim reports, temporary reports), the timing and content requirements, internal approval processes, and legal responsibilities. There is no actual financial data, financial statements, or specific report content such as an annual report or interim report. Instead, it is a governance document detailing how the company manages and controls its information disclosure obligations. Therefore, this document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices related to disclosure.
2021-11-11 Chinese
新乡拓新药业股份有限公司章程
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It contains detailed provisions about the company's organization, shareholder rights, board structure, share issuance, shareholder meetings, and other governance matters. It is a comprehensive governance document outlining the company's internal rules and regulations. There is no indication that this is an annual report, financial report, or an announcement. The content aligns with governance information about the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not a brief announcement or summary.
2021-11-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.